Adults with and without established cardiovascular disease who received ezetimibe with statin therapy had a modestly lower risk of major adverse CV events and all-cause mortality, compared with those who took statins alone, researchers reported in the Cochrane Database of Systematic Reviews. The findings were based on a systematic review and meta-analysis of 26 studies with 23,499 total individuals.
CVD events, mortality may be curbed with ezetimibe-statin combo
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.